Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol

S. Sciascia, M. Radin, I. Cecchi, A. Barinotti, E. Rubini, D. Rossi,
R. Fenoglio, A. Vaccarino, E. Menegatti, D. Roccatello

Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.

Abstract

Objective

To evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable to aPL [refractory and/or non-criteria manifestations of the antiphospholipid syndrome (APS)].

Methods

In this investigator-initiated, single-centre, open-label, prospective, phase II descriptive pilot trial, belimumab will be administered in 15 patients attending San Giovanni Bosco Hospital (Turin) showing refractory and/or non-criteria manifestations of APS. Subjects will receive belimumab 10 mg/kg intravenously (in addition to their ongoing APS treatment) with regimen at 0, 2, 4 weeks and every 4 weeks thereafter (up to week 104). Study endpoints determined at 4, 16, 24, 36, 52 and 104 weeks will include: primary (safety and adverse events) and secondary outcomes, such as changes in clinical outcomes (recurrent thromboses, thrombocytopenia, haemolytic anaemia, cardiovascular events, skin ulcer, aPL-related nephropathy and cognitive dysfunction), laboratory outcomes (routine tests, aPL, ENA and anti-dsDNA tests, thrombin generation assay, interferon-signature analysis, lymphocytes immunophenotyping, BLyS determination) and QoL evaluation.

Results

Study endpoints determined at 4, 16, 24, 36, 52 and 104 weeks will include: primary (safety and adverse events) and secondary outcomes, such as changes in clinical outcomes (recurrent thromboses, thrombocytopenia, haemolytic anaemia, cardiovascular events, skin ulcer, aPL-related nephropathy and cognitive dysfunction), laboratory outcomes (routine tests, aPL, ENA and anti-dsDNA tests, thrombin generation assay, interferon-signature analysis, lymphocytes immunophenotyping, BLyS determination) and QoL evaluation.

Conclusion

Targeting B-cells is emerging as an appealing strategy for patients with APS. Preliminary observations showed aPL negativisation after starting therapy with belimumab. The clinical relevance of these findings will be investigated in this prospective study. If confirmed, the current 'anti-thrombotic' approach to APS patients could be complemented, at least in selected cases, with an 'immunomodulatory' strategy.

Key words

antiphospholipid syndrome, antiphospholipid antibodies, belimumab, trial, autoimmunity

Savino Sciascia, MD, PhD*
Massimo Radin, MD, PhD*
Irene Cecchi, MD
Alice Barinotti, MSc
Elena Rubini, MD
Daniela Rossi, MD
Roberta Fenoglio, MD
Antonella Vaccarino, MD
Elisa Menegatti, MSc, PhD
Dario Roccatello, MD

*These authors contributed equally.

Please address correspondence to:
Savino Sciascia
Dipartimento di Scienze
Cliniche e Biologiche,
Università di Torino,
Ospedale S. Giovanni Bosco,
Piazza del Donatore di Sangue 3,
10154 Turin, Italy.
E-mail: savino.sciascia@unito.it

Introduction

The updated Sapporo classification criteria define antiphospholipid syndrome (APS) as vascular thromboses and/or recurrent pregnancy morbidity occurring in patients persistently positive for antiphospholipid antibodies (aPL), including lupus anticoagulant (LA), anti-cardiolipin antibodies (aCL), and anti-β2-glycoprotein I antibodies (aβ2GPI) (1). While APS is known for its vascular and obstetric manifestations, it is now recognised that its clinical spectrum is characterised by a wider number of aPL-related complications, such as cytopenia (mainly thrombocytopenia), cardiac valve disease (CVD), nephropathy, skin ulcers, *livedo reticularis*, and cognitive dysfunction, collectively referred to as non-criteria APS manifestations (1, 2).

On the one hand, APS is considered the most common acquired form of thrombophilia (2) and it can potentially affect the vascular system at any levels. Thrombotic events can occur in arteries, veins and microvasculature, leading to a vast set of clinical phenotypes. On the other hand, while thrombotic APS is the most common and investigated form of the disease, not all clinical features of APS can be explained by an underlying thrombotic mechanism. To date, only a limited number of studies has addressed the pathogenesis and treatment of non-criteria APS manifestations, which could require therapeutic strategies beyond antithrombotic approaches (2). Although the exact pathogenesis of extra-criteria manifestations of APS is far from being fully elucidated, they are believed to be caused by mechanisms other than thrombosis, such as phlogosis, activation of the complement pathway and platelet activation (3-5). Based on the differences in the pathogenesis, it is not surprising that traditional therapeutic approaches, mainly directed to counterbalance the pro-thrombotic status, are not sufficient when trying to treat patients with non-criteria manifestations, deeply affecting prognosis and outcomes of aPL positive patients. Therefore, different therapeutic approaches are highly needed in this subgroup of patients.

Our group recently reported aPL disappearance in three patients with APS associated with systemic lupus erythematosus (SLE) while on treatment with belimumab, potentially paving the way for the development of new targeted therapies for APS (6). Our preliminary observation was followed by other reports, further confirming the rationale for considering belimumab as an appealing strategy in APS patients (7, 8). Belimumab is a monoclonal antibody blocking the B-lymphocyte stimulator factor and avoiding B-cell activation and proliferation. It is the first biological drug approved for the treatment of autoantibody positive SLE in active phase and it has shown its capability to reduce the antibodies levels, including anti-dsDNA (9). Intriguingly, in murine models of APS in association with SLE, belimumab proved its ability to stop disease progression and to reduce mortality rate (10). However, its use in APS needs further investigation. It is currently unknown whether belimumab treatment eliminates clinically significant aPL or whether it is truly effective against aPL-related manifestations.

The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for aPL and clinical features attributable to aPL that are resistant to traditional anticoagulant treatment and/or classified among the non-criteria APS manifestations.

Methods

Study design

The BLAST trial is an investigator-initiated, single-centre, open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of APS. The study will be conducted at the San Giovanni Bosco Hospital (ASL Città di Torino and University of Turin, Italy). Figure 1 shows the time-line of the study, as well as the primary and secondary objectives of the trial.

Subjects will receive belimumab 10 mg/kg in addition to their ongoing APS treatment regimen. Belimumab will be

Fig. 1. Timeline of the study, including primary and secondary outcomes. In the lower arrow are represented the main time points corresponding to the infusion of belimumab, with particular emphasis on weeks 4, 16, 36, 52 and 104 during which will be evaluated the study endpoints. In the background the primary outcomes are illustrated: safety and adverse events. In the foreground are represented the main secondary outcomes: clinical outcomes [cognitive dysfunction, haemolitic anaemia, cardiac valve disease, skin ulcer, aPL-nephropathy, recurrent thrombosis and thrombocytopenia, laboratory outcomes [aPL titres reduction, thrombin generation assay, cytofluorimetry, interferon-signature and circulating BlyS levels] and quality of life evaluation [FACIT, PGA and PtGA]. The complete data analysis will be realised at the end of the study. [The figure was realised using BioRender (https://biorender.com)].

administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter (up to week 104). Study endpoints will be determined at 4, 16, 24, 36, 52 and 104 weeks.

The trial was approved by the local Ethical Board committee (2020-004568-25) and will be conducted according to the Declaration of Helsinki. The study was registered at ClinicalTrials.gov (identifier: NCT05020782).

Statistical analysis
Clinical characteristics, safety data (primary endpoint), and efficacy data (secondary endpoints) will be reported in a descriptive manner, using the mean ± SD and range. The proportion of patients who will achieve response (complete and partial response) in aPL profiles (4, 16, 36, 52 and 104 weeks) and clinical outcome measures (4, 16, 24, 36, 52 and 104 weeks) will be analysed as a categorical variable.
Categorical variables will be presented as number (%) and continuous variables will be presented as mean (S.D.).

The significance of baseline differences will be determined by the chi-squared test, Fisher's exact test or the unpaired t-test, as appropriate. Linear and logistic regressions will be performed. A ROC curve analysis will also be performed. A two-sided p-value <0.05 will be statistically significant. All statistical analyses will be performed using SPSS v. 26.0 (IBM, Armonk, NY, USA).

Sample size calculation
We based our sample calculation on a simple but robust approach to sample size estimation for single-arm phase II clinical trials with heterogeneous outcome probabilities (11). Recognition of patient heterogeneity relating to expected responses to particular therapeutic regimens is becoming increasingly common in clinical practice, and this approach formalises incorporation of this heterogeneity into the design of early phase II clinical trials.
The sample size of 15 patients was calculated with Bayesian Phase II Single

Arm Clinical Trials-Binary Outcomes based on previous experiences by Furie and colleagues (12). The authors found that 97% of patients treated with belimumab suffered for any side effect (55 out of 57). The majority of adverse events (AEs) were mild to moderate in severity. In detail, we based our calculation on the following assumptions:
1. It is assumed that number of AEs follow binomial distributions with proportion parameters for treatment group and control (controls for Furie *et al.*) (12) group. Proportion parameters are assumed to be random variables themselves possessing beta prior probability distribution with parameters $\alpha = \beta = 1$.
2. It is also known that for control group, there are 97% rates of AEs among 57 subjects. The Null and Alternative Hypotheses: the null hypothesis to be tested is that the rate of AEs in patients treated with belimumab with APS=control cohort, against the alternative hypothesis rate of AEs in patients with APS>AEs in patients with SLE as the control cohort.

*Patient characteristics,
inclusion and exclusion criteria*

APS patients without a concomitant diagnosis of SLE or other concomitant autoimmune conditions (primary APS-PAPS) followed at the San Giovanni Bosco Hospital (Turin, Italy) will be screened and included in the study when meeting the two following criteria:

1. Positive aPL-profile defined as:
Positive LA test as defined by the International Society on Thrombosis and Haemostasis, on two or more occasions, at least 12 weeks apart (13, 14) and/or positive aCL immunoglobulin (Ig)G/M/A isotype, present in >40U, on two or more occasions, at least 12 weeks apart and/or positive aβ2GPI IgG/M/A isotype, present in >40U, on two or more occasions, at least 12 weeks apart (14);

2. Clinical features attributable to aPL that are resistant to warfarin and/or heparin or listed among the so-called "extra-criteria" manifestations of APS, defined by at least one of the following:

- recurrent thrombosis despite ongoing anticoagulation;
- persistent thrombocytopenia;
- persistent autoimmune haemolytic anaemia;
- cardiac valve disease;
- chronic skin ulcers;
- renal thrombotic microangiopathy;
- cognitive dysfunction with/without white matter changes.

Table I summarises the exclusion criteria for the study. Medications concomitant to the use of warfarin and/or heparin that are not listed in Table I will be allowed. For instance, patients receiving anti-platelets agents, anti-malarials, anti-hypertensive drugs, statins and other medications to monitor lipid and vitamins intake will be included. Focusing on anti-malarials, the use of hydroxychloroquine will be allowed, but it will not be a necessary prerequisite for patients to be included in the study.

Laboratory testing

Selected laboratory values will be included in the analysed parameters (including routine laboratory testing such as full blood count, creatinine, liver enzymes, complement, immunoglobulins, coagulation testing, lipidic assessment, comprehensive metabolic panel, urinalysis).

With respect to complement testing, besides the commonly used tests evaluating the total complement activity and c3 and c4 fractions, more specific testing, such as those directed to complement activation products and regulators (*e.g.* CH50 and C5b9), will be employed in order to consider the different proteins involved in the complement cascade (15).

Table I. Exclusion criteria applied to this study.

Exclusion criteria
1. ≥4/11 American College of Rheumatology Classification Criteria for SLE
2. Acute thrombosis (arterial or venous acute thrombosis diagnosis less than 30 days before study screening)
3. History of stroke (only for patients with cognitive dysfunction)
4. Acute or chronic pancreatitis
5. Ongoing pregnancy
6. Significant cardiac or pulmonary disease (NYHA classification III-IV)
7. History of malignant neoplasm within the last 5 years (except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years)
8. Evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, poses a significant suicide risk
9. History of a primary immunodeficiency
10. Significant IgG deficiency (IgG level <400 mg/dL)
11. IgA deficiency (IgA level <10 mg/dL)
12. Known active bacterial, viral fungal mycobacterial, or other infection
13. Infectionhistory:
    - currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria)
    - hospitalisation for treatment of infection within 60 days of Day 0
    - use of parenteral (IV or IM) antibiotics (anti-bacterial, antiviral, anti-fungal, or anti-parasitic agents) within 60 days of Day 0
14. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 365 days prior to day 0
15. Historically positive HIV test or test positive at screening for HIV
16. Hepatitis status:
    - Serologic evidence of current or past hepatitis B (HB) infection based on the results of testing for HBsAg and HBcAb as follows:
    - patients positive for HBsAg or HBcAb are excluded
    - positive test for hepatitis C antibody
17. History of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies
18. Any other clinically significant abnormal laboratory value in the opinion of the investigator
19. If Women of Child-Bearing Potential (WCBP) are included, please see special instructions:
    - urine or serum pregnancy testing acceptable
    - timing of pregnancy test must be <7 days prior to first dose
    - pregnancy testing for IV belimumab - prior to each IP administration, but not more than once a month
    - at least 4 months (5 half-lives) post last dose
20. Have any intercurrent significant medical or psychiatric illness that the investigator considers would make the candidate unsuitable for the study

Excluded concomitant medications
1. Anti-B cell therapy:
    - wash-out of 5 therapeutic half-lives after prior B-cell therapy, or until pharmacodynamic effect would be minimal (*e.g.* 1 year following rituximab)
2. 365 days prior to belimumab:
    - any biologic investigational agent (*e.g.* abetimus sodium, anti-CD40L antibody, BG9588/IDEC 131)
    (investigational agent applies to any drug not approved for sale in the country in which it is being used)
3. 90 days prior to belimumab:
    - intravenous cyclophosphamide
    - subjects receiving CYC whose leukocyte count is <2000/m3
4. 30 days prior to belimumab (or 5 half-lives, whichever is greater):
    - any non-biologic investigational agent
    (investigational agent applies to any drug not approved for sale in the country in which it is being used)
5. Live vaccines within 30 days prior to baseline or concurrently with belimumab

A specialised immunological laboratory test will also be performed, to include aPL, antinuclear, extractable nuclear antibodies and anti-dsDNA antibodies, as previously described (16, 17). Patients will be tested also for experimental techniques such as thrombin generation assay (TGA), interferon (IFN) signature, BLyS determination, lymphocytes immunophenotyping, extra-criteria aPL testing, as previously described (6, 18, 19).

Outcome measures
- Primary outcome measures
The primary outcome of the study will be the number of participants experiencing serious and non-serious AEs (time points for evaluation: 4, 16, 24, 36, 52 and 104 weeks).

Definitions of serious and non-serious AEs are further described in the Supplementary file.

- Secondary outcome measures
The efficacy of belimumab will be evaluated based on the baseline clinical manifestations of the patients. In detail, outcome measures will be classified as complete response (CR), partial (PR), and none (NR) at 4, 16, 24, 36, 52 and 104 weeks.

Response for the various clinical manifestations will be defined has follows:
- for recurrent thrombosis despite anticoagulation, CR will be defined as no events, PR as occurrence superficial thrombotic events, and NR as occurrence of venous;
- for persistent thrombocytopenia, CR defined as platelet count of $\geq150\times10^6/\mu l$, PR as $100\text{-}149\times10^6/\mu l$, and NR as $<100 \times10^6/\mu l$;
- for persistent autoimmune haemolytic anaemia, CR as haemoglobulin concentration of 14-18 g/dL (males) or 12–16 g/dL (females), PR as 11–14 g/dL (males) or 10–12 g/dL (females), and NR as <11 g/dL (males) or <10 g/dL (females);
- for skin ulcer, CR is defined as disappearance, PR as 50% improvement, and NR as no change;
- for renal thrombotic microangiopathy, CR defined as a normal serum creatinine level, inactive urinary sediment, and urinary protein: creatinine 0.5; PR as a serum creatinine level 15% above baseline, RBCs per high-power field 50% above baseline with no casts, 50%improvement in the urinary prt:cr, and estimated GFR 10% above baseline; and NR as the absence of C/PR;
- for cognitive dysfunction, the Cognitive Impairment Index (CII) (20) will be used to assess the perception of cognitive decline in memory, executive function, and language domains from both self and clinicians perspectives: CR is defined as normalisation of the CII with a 50% improvement, PR as abnormal index with 50%, and NR as no change.

Other measures that will be included in the study are the following:
- rate of documented thrombotic events;
- reduction in aPL levels, both *criteria* and *non-criteria,* assed at 4, 16, 24, 36, 52 and 104 weeks;
- change from baseline in Physician Global Assessment (PGA) at 4, 16, 24, 36, 52 and 104 weeks (PGA is a physician-reported visual analogue scale that provides an overall measure of the subject's current disease activity);
- change from baseline in Patient Global Assessment (PtGA) at 4, 16, 24, 36, 52 and 104 weeks [in PtGA subjects will be asked to rate the severity of their SLE between 0 (very well) and 10 (very poor) that best represents their current level of disease activity];
- change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score and Proportion of subjects with improvement in FACIT-Fatigue score exceeding the Minimal Clinically Important Difference (MCID, ≥4) at 4, 16, 24, 36, 52 and 104 weeks (FACIT-Fatigue scale includes 13-fatigue related questions for subject rates fatigue during the previous 7 days, yielding an overall score 0 to 52, with lowest score representing worst fatigue);
- normalisation of TGA profile, assessed at 4, 16, 24, 36, 52 and 104 weeks;
- reduction of the IFN signature, assed at 4, 16, 24, 36, 52 and 104 weeks;
- reduction of circulating Blys deter-mination, assessed at 4, 16, 24, 36, 52 and 104 weeks;
- normalisation of lymphocytes' immunophenotyping, assessed at 4, 16, 24, 36, 52 and 104 weeks.

Benefit-risk assessment
Expected beneficial effects
There are currently no available tools to assess disease activity and therefore the efficacy of treatment in APS patients. However, based on the complexity of the disease, it is agreed that a single tool might not be sufficient in the assessment of disease activity in individual patients.

The following considerations will be based on benefit-risk balance in SLE, a different clinical condition when compared to APS. However, APS and SLE shared several immunological features and they often overlap, creating a solid ground for some shared considerations. Both conditions are sustained by a pathogenic role of autoantibodies, and belimumab has been found to be an effective agent in reducing autoantibodies titres in both APS and SLE (6, 21). When extrapolating some considerations from SLE trials, both belimumab Phase III trials (C1056 and C1057) (22, 23) achieved a significantly higher responder rate for the treatment dose applied for 10 mg/kg compared with placebo. Belimumab treatment demonstrated beneficial effects with higher rates of reductions in disease activity in a population with involvement of vascular, musculoskeletal, immunology, and mucocutaneous organs. In C1056 study, belimumab 10 mg/kg, in addition to standard therapy, yielded 9.41% (p=0.0207, OR=1.52, 95% CI=1.07, 2.15) more responders at week 52 as compared to standard therapy only. In study C1057, 14% (p=0.0006, OR=1.83, 95% CI=1.30, 2.59) more responders were the results of additional analyses and it has been showed a clinically relevant treatment effect in patients with high disease activity as expressed by higher level of anti-dsDNA antibodies. In fact, a more robust benefit is seen in this subset of patients while limited, or even null benefit might be expected in the anti-dsDNA negative population.

Uncertainty in the knowledge about the beneficial effects

The feasibility of describing the appropriate target population in an indication wording has been extensively discussed during the last years. There is a good level of agreement on the fact that APS patients refractory to standard anticoagulation need further options beyond vitamin K antagonist and heparins.

The effect of belimumab has been demonstrated in a SLE patient population with mainly musculoskeletal, vascular, mucocutaneous and hematological involvement, which shared some clinical features with APS (namely vascular involvement and cytopenia) (6, 24, 25). Whether the effect will remain in patients with involvement of vital organ/systems (cardiovascular/respiratory, central nervous system and renal) is unknown. Similarly to SLE, there are some uncertainties concerning optimal treatment duration, maintenance doses, treatment holidays and rebound phenomenon.

Risk of unfavourable effects

In the placebo-controlled IV SLE controlled repeat dose studies (*i.e.* primary safety population), the incidence and distribution of AEs was generally fairly similar between the placebo group and the 1 mg/kg and 10 mg/kg belimumab groups (22, 23). Common events that were reported slightly more frequent in both belimumab groups compared with placebo included: nausea, diarrhoea, nasopharyngitis, bronchitis, pain in extremity, and depression. Other events that were more commonly reported in the 10 mg/kg belimumab group compared with placebo included leukopenia, pyrexia, cystitis, viral gastroenteritis, migraine and insomnia. However, the differences in incidence between the treatment groups for these common events were small. Similarly, the incidence of SAEs in the controlled SLE studies was similarly distributed across the treatment groups. In the long-term open-label continuation studies, the overall incidence of events did not appear to increase over time, and some events declined. Relatively few subjects discontinued because of an AE. The AEs data in the RA stud-

ies (secondary safety population) were consistent with the IV SLE controlled repeat dose studies (CRD) (26).

Taking the above together, we expect a very similar safety profile of belimumab in APS when compared to SLE, also taking into account the similarity between these diseases. Since belimumab is a biologic agent inhibiting the survival and differentiation of B cells, additional important events were considered: mainly the risk of infection and malignancy. In the IV SLE CRD studies, the incidence of infections was generally comparable between the 1 mg/kg and 10 mg/kg belimumab treatment groups compared with placebo, with the exception of bronchitis and nasopharyngitis, which were slightly more common in the belimumab groups. The incidence of serious bronchitis was also higher for belimumab (0.4% in the 10 mg/kg group compared with 0.1% for placebo). The incidence of sepsis was low but also somewhat higher for belimumab compared with placebo (0.7% for the 10 mg/kg group compared with 0.4% for placebo). There were five SAEs of sepsis (0.7% of subjects) in the belimumab 10 mg/kg group compared with one subject (0.1%) in the placebo group. Overall, there were no significant differences regarding Grade 3 or Grade 4 lymphopenia, neutropenia and IgG levels between the placebo and the belimumab 1 mg/kg or 10 mg/kg groups in the controlled SLE studies. However, subjects in the belimumab groups who experienced Grade 3 or Grade 4 lymphopenia, neutropenia, or low IgM or IgG exhibited slightly higher rates of infections *versus* placebo and *versus* subjects without these abnormalities.

Again, we expect a similar safety profile of belimumab in APS when compared to SLE in terms of risk of infection. Ideally, due to the fact that patients with APS are not routinely treated with immunosuppressive agents, the risk of infection could be expected to be even lower when compared to SLE.

Uncertainty in the knowledge about the unfavourable effects

Belimumab is a human monoclonal antibody that specifically binds and inhibits the activity of soluble human

BLyS, a member of the tumour necrosis factor (TNF)-ligand superfamily. BLyS promotes B-cell differentiation, proliferation, and Ig class switching and survival. Risks that may be associated with the use of immunomodulators in general are the risk of (opportunistic) infections and the potential risk for malignancy (27-29). It is not known to what degree these potential concerns may also apply to belimumab.

In general, in the placebo-controlled IV SLE CRD studies, the incidence and distribution of AEs was fairly similar between the placebo group and the 1 mg/kg and 10 mg/kg belimumab groups, which would be indicative of a generally favourable safety profile. As previously stated, due to the fact that patients with APS are not routinely treated with immunosuppressive agents, the risk of infection could be expected to be even lower when compared to SLE.

A significant increase in infection incidence was not observed in the belimumab studies. The number of deaths related to sepsis in the controlled studies was slightly higher in the belimumab groups, compared with placebo. However, a possible relationship to belimumab was not always clear since it was used as an add-on treatment to standard of care SLE therapy, which typically includes other immunosuppressant drugs; this is not the case of APS.

While cases of progressive multifocal leukoencephalopathy (PML) have been reported for other immunosuppressive drugs, to date no cases have been reported for belimumab. There were slightly more reports of psychiatric disorders in the belimumab groups compared with placebo. The differences were small but the reasons are unclear, considering that belimumab primarily acts on B-cells. Long-term follow-up data will be of value to determine whether there is a signal.

No particular trends regarding malignancy were observed in the relatively short observation period of 52 weeks of controlled data. In general, it is known that the risk of malignancy is greater in patients with SLE compared with a non-SLE population but no solid data are available for APS (30-32). Across the Phase II and III IV SLE studies

(LBSL02, C1056, C1057, and the open-label study LBSL99), the rate of malignant neoplasms (excluding NMSC) per 100-subjectyears with belimumab was similar to the rate observed in a large international SLE cohort study (22, 23, 33, 34). Overall, no conclusions can be drawn with some certainty until more and longer duration follow-up data are available. No particular trends regarding malignancy were observed in the relatively short observation period of 52 weeks of controlled data.

Benefit-risk balance
There is an unmet medical need for novel options in APS treatment, especially in cases refractory to vitamin k antagonist and heparins or in the presence of the extra-criteria manifestations. In fact, no immunomodulatory drug has been approved for the indication of APS.
While a limited number of treatment options are available for APS, many patients suffer from recurrences despite ongoing treatment, resulting in irreversible damage to internal organ systems. Standard therapy includes anticoagulation and anti-platelets agents, aiming to counterbalance the pro-thrombotic status, but with no proven effect on the pathogenesis of the disease. Consequently, a new drug providing additional disease control or presenting a more favourable safety profile when compared to life-long anticoagulation would be considered of clinical value.
Alternative analyses performed for the two pivotal Phase III studies support a clinically relevant treatment effect of belimumab in reducing autoantibodies titres and this observation creates a promising background for its use in APS. In SLE a substantially increased likelihood of a treatment response has been shown for the subpopulation of anti-dsDNA antibodies positive patients (9, 35-38).
The addition of 10 mg/kg belimumab to standard SLE therapy was generally well tolerated, although a small increase in infections incidence was observed. Some patients developed infusion related reactions, some of which were reminiscent of hypersensitivity reactions. The mechanism of these reactions has not been clarified. In any case, this is not considered a major obstacle against belimumab use if appropriate preventive measures are taken. Besides, due to the lack of concomitant immunosuppressive therapy, when compared to SLE, APS patients are supposed to have a lower *a priori* risk for infections.
Potential concerns relating to the long-term use of immunomodulators in general are the risk for (opportunistic) infections and the potential risk for malignancy. It is not known to what degree these potential concerns also apply to a compound such as belimumab. Given that SLE is a life-long illness that requires chronic treatment, identification of such risks is of great importance.

Conclusions
In conclusion, the combined favourable effects of belimumab treatment might be considered to outweigh the unfavourable effects. Results from alternative analyses in SLE support a larger effect in patients with high levels of autoantibodies, indicating that belimumab could be valuable for APS patients. The safety profile for this patient subgroup does not appear to be significantly different to the safety profile for the overall study population and consequently the benefit-risk is considered positive.
Belimumab represents a novel concept to treat APS patients aiming to target the pathogenic antibodies at the base of the disease. Thus, uncertainty exists regarding the potential for development of malignancies, as well as other potential long-term risks such as increased risk of developing opportunistic infections, or PML. This emphasises the need for a proper long-term follow up.
All in all, being APS a disease orphan of a tailored therapy, targeting B-cells is emerging as an appealing strategy, especially when thrombosis recurs despite well-conducted anticoagulation or when extra-criteria manifestations occur. Preliminary observations showed aPL-negativisation after starting belimumab therapy. This study has the potential to explore the clinical relevance of these findings in a prospective fashion. If confirmed, the current 'anti-thrombotic' approach to APS patients could be complemented, at least in selected cases, with an 'immunomodulatory' strategy.

References
1. MIYAKIS S, LOCKSHIN MD, ATSUMI T *et al*.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; 4(2): 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
2. SCIASCIA S, AMIGO MC, ROCCATELLO D, KHAMASHTA M: Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. *Nat Rev Rheumatol* 2017; 13(9): 548-60. https://doi.org/10.1038/nrrheum.2017.124
3. RUIZ-IRASTORZA G, CROWTHER M, BRANCH W, KHAMASHTA MA: Antiphospholipid syndrome. *Lancet* 2010; 376(9751): 1498-509. https://doi.org/10.1016/s0140-6736(10)60709-x
4. SCIASCIA S, ROCCATELLO D, BERTERO MT *et al*.: 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. *Inflamm Res* 2012; 61(8): 809-16. https://doi.org/10.1007/s00011-012-0468-0
5. GIANNAKOPOULOS B, KRILIS SA: The pathogenesis of the antiphospholipid syndrome. *N Engl J Med* 2013; 368(11): 1033-44. https://doi.org/10.1056/nejmra1112830
6. SCIASCIA S, RUBINI E, RADIN M, CECCHI I, ROSSI D, ROCCATELLO D: Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. *Ann Rheum Dis* 2018; 77(11): 1693-5. https://doi.org/10.1136/annrheumdis-2018-213496
7. BETTIOL A, PREGNOLATO F, SCIASCIA S *et al*.: Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou *et al*. *Ann Rheum Dis* 2022; 81(8): e140. https://doi.org/10.1136/annrheumdis-2020-218377
8. EMMI G, BETTIOL A, PALTERER B *et al*.: Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment. *Autoimmun Rev* 2019; 18(3): 312-14. https://doi.org/10.1016/j.autrev.2018.11.002
9. RADIN M, CECCHI I, SCHREIBER K *et al*.: Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. *Expert Opin Orphan Drugs* 2016; 5: 55-69. https://doi.org/10.1080/21678707.2017.1257937
10. KHATTRI S, ZANDMAN-GODDARD G, PEEVA E: B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data. *Autoimmun Rev* 2012; 11(10): 717-22. https://doi.org/10.1016/j.autrev.2011.12.011
11. Sample Size Calculation for Single-Arm Phase 2 Prostate Cancer Trials | Personalized Medicine in Oncology, http://www.

personalizedmedonc.com/publications/pmo/december-2015-vol-4-no-6/sample-size-calculation-for-single-arm-phase-2-prostate-cancer-trials/ (accessed 19 October 2021).

12. FURIE R, STOHL W, GINZLER EM *et al.*: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. *Arthritis Res Ther* 2008; 10(5): R109. https://doi.org/10.1186/ar2506

13. PENGO V, TRIPODI A, REBER G *et al.*: Update of the guidelines for lupus anticoagulant detection. *J Thromb Haemost* 2009; 7(10): 1737-40. https://doi.org/10.1111/j.1538-7836.2009.03555.x

14. FODDAI SG, RADIN M, CECCHI I *et al.*: The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. *J Thromb Haemost* 2020; 18(11): 2921-8.

15. KIRSCHFINK M, MOLLNES TE: Modern complement analysis. *Clin Diagn Lab Immunol* 2003; 10: 982.

16. RADIN M, SCHREIBER K, CECCHI I *et al.*: A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. *Rheumatology* (Oxford) 2020; 59: 2412-18. https://doi.org/10.1111/jth.15053

17. RADIN M, RUBINI E, CECCHI I *et al.*: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. *Clin Exp Rheumatol* 2022; 40(3): 575-80. https://doi.org/10.55563/clinexprheumatol/7vp1bo

18. CECCHI I, RADIN M, RODRÍGUEZ-CARRIO J, TAMBRALLI A, KNIGHT JS, SCIASCIA S: Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. *Expert Rev Clin Immunol* 2021; 17(4): 395-406. https://doi.org/10.1080/1744666x.2021.1901581

19. RADIN M, BARINOTTI A, FODDAI SG *et al.*: Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. *Immunol Res* 2021; 69(4): 372-7. https://doi.org/10.1007/s12026-021-09208-1

20. RATTANABANNAKIT C, RISACHER SL, GAO S *et al.*: The Cognitive Change Index as a measure of self and informant perception of cognitive decline: relation to neuropsychological tests. *J Alzheimers Dis* 2016; 51(4): 1145. https://doi.org/10.3233/jad-150729

21. STOHL W, HIEPE F, LATINIS KM *et al.*: Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. *Arthritis Rheum* 2012; 64(7): 2328-37. https://doi.org/10.1002/art.34400

22. A continuation trial for subjects with lupus that completed protocol HGS1006-C1056 or HGS1006-C1057 - Full Text View - ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00712933 (accessed 19 October 2021).

23. A continuation trial for subjects with lupus who completed protocol HGS1006-C1056 in the United States - Full Text View - ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00724867 (accessed 19 October 2021).

24. VILAS-BOAS A, MORAIS SA, ISENBERG DA: Belimumab in systemic lupus erythematosus. *RMD Open* 2015; 1(1): e000011. https://doi.org/10.1136/rmdopen-2014-000011

25. YAZICI A, YAZIRLI B, ERKAN D: Belimumab in primary antiphospholipid syndrome. *Lupus* 2017; 26(10): 1123-4. https://doi.org/10.1177/0961203316682102

26. STOHL W, MERRILL JT, McKAY JD *et al.*: Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. *J Rheumatol* 2013; 40(5): 579-89. https://doi.org/10.3899/jrheum.120886

27. CHEN M, ZHAO Y, XU C, WANG X, ZHANG X, MAO B: Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. *Ann Hematol* 2018; 9786): 925-44. https://doi.org/10.1007/s00277-018-3284-y

28. DURCAN L, PETRI M: Immunomodulators in SLE: Clinical evidence and immunologic actions. *J Autoimmun* 2016; 74: 73-84. https://doi.org/10.1016/j.jaut.2016.06.010

29. BASCONES-MARTINEZ A, MATTILA R, GOMEZ-FONT R, MEURMAN JH: Immunomodulatory drugs: oral and systemic adverse effects. *Med Oral Patol Oral Cir Bucal* 2014; 19(1): e24-31. https://doi.org/10.4317/medoral.19087

30. LADOUCEUR A, CLARKE AE, RAMSEY-GOLD-MAN R, BERNATSKY S: Malignancies in systemic lupus erythematosus: an update. *Curr Opin Rheumatol* 2019; 31(6): 678-81. https://doi.org/10.1097/bor.0000000000000648

31. CADER RA, MEI YEE AK, YASSIN A, AHMAD I, HARON SN: Malignancy in systemic lupus erythematosus (SLE) patients. *Asian Pac J Cancer Prev* 2018; 19(12): 3551-5. https://doi.org/10.31557/apjcp.2018.19.12.3551

32. CHOI MY, FLOOD K, BERNATSKY S, RAMSEY-GOLDMAN R, CLARKE AE: A review on SLE and malignancy. *Best Pract Res Clin Rheumatol* 2017; 31(3): 373-96. https://doi.org/10.1016/j.berh.2017.09.013

33. A continuation trial for subjects with systemic lupus erythematosus that have completed protocol LBSL02 - Full Text View - ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00583362 (accessed 20 October 2021).

34. Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects with Systemic Lupus Erythematosus (SLE) - Full Text View - ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT00071487?term=LBSL99&draw=2&rank=1 (accessed 20 October 2021).

35. SCIASCIA S, RADIN M, YAZDANY J *et al.*: Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. *Autoimmun Rev* 2017; 16(3): 287-93. https://doi.org/10.1016/j.autrev.2017.01.010

36. STRAND V, BERRY P, LIN X *et al.*: Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. *Arthritis Care Res* (Hoboken) 2019; 71(6): 829-38. https://doi.org/10.1002/acr.23788

37. FURIE R, PETRI M, ZAMANI O *et al.*: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum* 2011; 63(12): 3918-30. https://doi.org/10.1002/art.30613

38. WALLACE DJ, STOHL W, FURIE RA *et al.*: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. *Arthritis Rheum* 2009; 61(9): 1168-78. https://doi.org/10.1002/art.24699